Results 101 to 110 of about 1,991 (194)

Hypertrophic Cardiomyopathy: Current Perspectives

Reviews in Cardiovascular Medicine
Hypertrophic cardiomyopathy (HCM) is a multifaceted genetic disorder characterized by left ventricular hypertrophy (LVH) in the absence of alternative causes, with an estimated prevalence ranging from 1 in 200 to 1 in 500 individuals. Since HCM was first
Dhruvil Patel, Ruchika Bhargav, Aliaa Mousa, Sabahat Bokhari   +3 more
doaj   +1 more source

Efficacy and safety of cardiac myosin inhibitors for symptomatic hypertrophic cardiomyopathy: a meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine
IntroductionHypertrophic cardiomyopathy (HCM) is a common genetic heart disorder. It is characterized by left ventricular hypertrophy and impaired cardiac function, with forms categorized into obstructive (oHCM) and nonobstructive (nHCM).
Anas Abunada, Madiha Shah, Ateesh Kumar, Syeda Lamiya Mir, Dinesh Kumar, Saboor Ahmed, Muhammad Tanzeel, Vikash Kumar, Aashish Meghjiani, Muhammad Basit Ali Siddiqui, Govinda Khatri, Aneesh Rai, Fnu Deepak, Ayush Kumar   +13 more
doaj   +1 more source

Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside [PDF]

, 2022
Coppini, Raffaele, Olivotto, Iacopo, Palandri, Chiara, Santini, Lorenzo   +3 more
core   +1 more source

Exploring contractile protein mechanisms and target medications for cardiomyopathic patients with diastolic dysfunction

Pediatric Discovery
Genetic defects have been increasingly found in cardiomyopathies, which are often present with mutations in cardiac contractile proteins. These congenital defects involve numerous intracellular pathways and share several critical clinical features, such ...
Dustin Gerber, Junjun Quan, Bo Pan, Xupei Huang, Jie Tian   +4 more
doaj   +1 more source

Mavacamten has a differential impact on force generation in myofibrils from rabbit psoas and human cardiac muscle [PDF]

, 2021
Coppini, R., Dente, M., Ferrantini, C., Pioner, J. M., Piroddi, N., Poggesi, C., Scellini, B., Tesi, C., Vitale, G.   +8 more
core   +1 more source

Correction to: Mavacamten: First Approval

Drugs, 2022
openaire   +1 more source

Sarcomere protein modulation: The new frontier in cardiovascular medicine and beyond [PDF]

, 2022
Olivotto, Iacopo
core   +1 more source

Hemodynamic Implications After Left Ventricular Outflow Tract Obstruction Relief With Mavacamten. [PDF]

JACC Case Rep
Kitai T, Zhang J, Saku K.
europepmc   +1 more source

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy. [PDF]

J Am Heart Assoc
Ibrahim R, Wang W, Pham HN, Abdelnabi M, Lester SJ, Wilansky S, Schaff HV, Geske JB, Arsanjani R, Ayoub C.   +9 more
europepmc   +1 more source

Managing drug–drug interactions with mavacamten: A focus on combined use of antiarrhythmic drugs and anticoagulants [PDF]

Olivotto, Iacopo
core   +1 more source